UBS Group’s TC BioPharm (Holdings) plc Warrants TCBPW Stock Holding History

UBS Group’s Portfolio TCBPW Stock Details TCBPW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-2,400	Closed	-$24	–	10954
2024 Q4	$24	Buy	2,400 +1,219	+103%	+$21	﹤0.01%	9768
2024 Q3	$21	Buy	1,181 +1,147	+3,374%	+$17	﹤0.01%	9310
2024 Q2	$0	Sell	34 -1,060	-97%	-$18	﹤0.01%	10266
2024 Q1	$22	Sell	1,094 -12,515	-92%	-$229	﹤0.01%	9026
2023 Q4	$449	Buy	13,609 +13,503	+12,739%	+$316	﹤0.01%	8653
2023 Q3	$1	Sell	106 -4,079	-97%	-$151	﹤0.01%	9382
2023 Q2	$180	Buy	4,185 +3,985	+1,993%	+$251	﹤0.01%	8424
2023 Q1	$20	Buy	+200	New	+$25	﹤0.01%	9420

UBS Group's TCBPW Position: Q1 2025 in Review

UBS Group sold out of TC BioPharm (Holdings) plc Warrants (TCBPW) in Q1 2025, closing a stake of 2,400 shares — an estimated $24 sold.

UBS Group first reported a position in TCBPW in Q1 2023 and held it in 8 quarters. The position peaked at $449 in Q4 2023. 0 funds tracked by Wall St. Rank hold TCBPW as of Q1 2025.

UBS Group reported no remaining TC BioPharm (Holdings) plc Warrants position as of Q1 2025 after selling out during the quarter.
UBS Group sold 2,400 TC BioPharm (Holdings) plc Warrants shares in Q1 2025, an estimated $24.
UBS Group first reported a position in TC BioPharm (Holdings) plc Warrants in Q1 2023 and held it in 8 quarters.
UBS Group's TC BioPharm (Holdings) plc Warrants position peaked at $449 in Q4 2023.
0 funds tracked by Wall St. Rank held TC BioPharm (Holdings) plc Warrants as of Q1 2025.

Based on UBS Group's 13F filing for Q1 2025, filed 13 May 2025.